Advertisement

Topics

Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s

20:30 EDT 14 Sep 2018 | Xconomy

A Teva Pharmaceutical migraine-prevention drug has won FDA approval, the second therapy in this new drug class to receive the regulatory nod this year. The Friday approval for the Teva (NYSE: TEVA) drug fremanezumab (Ajovy) came a little earlier than expected; the target date for the FDA decision was Sept. 16. The drug is part […]

Original Article: Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s

NEXT ARTICLE

More From BioPortfolio on "Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen’s"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...